Pruritus
- May 2022
- 15min
Therapeutic classes inducing this adverse event
Antiangiogenic agent, BRAF inhibitor, CTLA4 inhibitor, Chemotherapy, Cyclin-dependent kinase 4/6 inhibitor, EGFR inhibitor, Hormone therapy, KIT inhibitor, MEK inhibitor, PD-1 inhibitor, RAF inhibitor, Radiotherapy, SMO inhibitor, mTOR inhibitor
- 1/2
- 2/2
CTCAE V5.0
Mild or localized; topical intervention indicated
SIMPLIFIED GRADING
Localized
No or mild discomfort
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Widespread and intermittent; skin changes from scratching (e.g., edema, papulation, excoriations, lichenification, oozing/crusts); oral intervention indicated; limiting instrumental ADL
SIMPLIFIED GRADING
Widespread and intermittent
Skin changes from scratching (excoriations, lichenification, etc.)
Limiting instrumental ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Widespread and constant; limiting self care ADL or sleep; systemic corticosteroid or immunosuppressive therapy indicated
SIMPLIFIED GRADING
Widespread and constant, limiting sleep
Skin changes from scratching (excoriations, lichenification, etc.)
Limiting self care ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events